| AIS | Acute Ischemic Stroke |
| AHA/ASA | American Heart Association/American Stroke Association |
| aOR | Adjusted Odds Ratio |
| APT | Antiplatelet Therapy |
| ASPECTS | Alberta Stroke Program Early CT Score |
| BBB | Blood–Brain Barrier |
| CT | Computed Tomography |
| CT-P | Computed Tomography Perfusion |
| DWI | Diffusion-Weighted Imaging |
| eTICI | Expanded Thrombolysis in Cerebral Infarction |
| EVT | Endovascular Thrombectomy |
| GP | Glycoprotein |
| GPVI | Glycoprotein VI |
| HIR | Hypoperfusion Intensity Ratio |
| IA | Intra-Arterial |
| ICAD | Intracranial Atherosclerotic Disease |
| ICH | Intracranial Hemorrhage |
| IL-6 | Interleukin-6 |
| IV | Intravenous |
| IVT | Intravenous Thrombolysis |
| LVO | Large Vessel Occlusion |
| mRS | Modified Rankin Scale |
| MRI | Magnetic Resonance Imaging |
| mTICI | Modified Thrombolysis in Cerebral Infarction |
| MT | Mechanical Thrombectomy |
| OR | Odds Ratio |
| RCT | Randomized Controlled Trial |
| RCTs | Randomized Controlled Trials |
| ROS | Reactive Oxygen Species |
| SBP | Systolic Blood Pressure |
| sICH | Symptomatic Intracranial Hemorrhage |
| STAIR | Stroke Therapy Academic Industry Roundtable |
| SUR1 | Sulfonylurea Receptor 1 |
| TICI | Thrombolysis in Cerebral Infarction |
| TLR4 | Toll-Like Receptor 4 |
| Tmax | Time-to-Maximum of the Residue Function |
| TNK | Tenecteplase |